Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that ...
Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that ...
Medindia2d
Lucid Diagnostics Announces Updated National Comprehensive Cancer Network (NCCN) Guidelines Now Include Esophageal Precancer Screening
Lucid Diagnostics Inc.�(Nasdaq: LUCD)�("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, a ...
BTIG Keeps Their Buy Rating on Lucid Diagnostics (LUCD)
In a report released yesterday, Mark Massaro from BTIG reiterated a Buy rating on Lucid Diagnostics (LUCD – Research Report), with a price ...
Morningstar3d
Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication
Study confirms clinical utility of EsoGuard as a non-invasive triage tool to significantly increase positive yield of invasive upper endoscopy The ENVET-BE study reviewed real-world data from a ...
Finanznachrichten3d
Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard Esophageal Precancer Testing Accepted for Peer-Reviewed Publication
About Lucid Diagnostics Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions ...
CWRU, UH researchers test noninvasive esophageal cancer screening technology
A multi-site study, backed by an $8 million NIH grant, will evaluate the effectiveness of Lucid Diagnostics' EsoCheck and ...
Le Lézard3d
Nanalysis Announces Release of Automation Software
Nanalysis Scientific Corp. ("the Company", TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1), a leader in portable NMR instruments and imaging technology and services for industrial and research applications, ...
Le Lézard3d
NKF Honors SeaStar Medical, with 2025 Corporate Innovator Award
SeaStar Medical has been selected to receive the 2025 Corporate Innovator Award from the National Kidney Foundation (NKF) at the 2025 Spring Clinical Meetings in ...
BioSpace2d
Lucid Diagnostics’ ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication
Study confirms clinical utility of EsoGuard as a non-invasive triage tool to significantly increase positive yield of invasive upper endoscopy The ENVET-BE study reviewed real-world data from a cohort ...